[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100570839":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":16,"locations":25,"responsibleParty":142,"collaborators":7,"id":144,"slug":145,"hasResults":146,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":7,"eligibilityCriteria":149,"healthyVolunteers":146,"sex":150,"minAge":151,"maxAge":7,"enrollmentInfo":152,"targetDuration":7,"studyType":155,"phases":7,"briefSummary":156,"conditions":157,"keywords":7,"overallStatus":63,"whyStopped":7,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"International Extranodal Lymphoma Study Group (IELSG)","OTHER",null,[9,13],{"name":10,"affiliation":11,"role":12},"Luca Arcaini, MD","Fondazione IRCCS Policlinico San Matteo","STUDY_CHAIR",{"name":14,"affiliation":15,"role":12},"Davide Rossi, MD","Oncology Institute of Southern Switzerland (IOSI) and Institute of Oncology Research (IOR)",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},"IELSG Study Coordination Office","CONTACT","+41 58 666 7321","ielsg@ior.usi.ch",{"name":14,"role":19,"phone":23,"phoneExt":7,"email":24},"+41 91 811 8540","davide.rossi@eoc.ch",[26,45,61,78,92,110,126],{"facility":27,"status":28,"city":29,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Columbia University","NOT_YET_RECRUITING","New York","10032","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-74.00597,40.71427,{"lat":37,"lon":36},[40,43],{"name":41,"role":19,"phone":7,"phoneExt":7,"email":42},"Govind Bhagat, MD","gb96@cumc.columbia.edu",{"name":41,"role":44,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"facility":46,"status":28,"city":47,"state":7,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Universitz Hospitals Leuven","Leuven","3000","Belgium","BE",{"type":34,"coordinates":52},[53,54],4.70093,50.87959,{"lat":54,"lon":53},[57,60],{"name":58,"role":19,"phone":7,"phoneExt":7,"email":59},"Thomas Tousseyn, MD","thomas.tousseyn@kuleuven.be",{"name":58,"role":44,"phone":7,"phoneExt":7,"email":7},{"facility":62,"status":63,"city":64,"state":7,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Hôpital Saint Louis","RECRUITING","Paris","75475","France","FR",{"type":34,"coordinates":69},[70,71],2.3488,48.85341,{"lat":71,"lon":70},[74,77],{"name":75,"role":19,"phone":7,"phoneExt":7,"email":76},"Catherine Thieblemont, MD","catherine.thieblemont@aphp.fr",{"name":75,"role":44,"phone":7,"phoneExt":7,"email":7},{"facility":11,"status":63,"city":79,"state":7,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Pavia","27100","Italy","IT",{"type":34,"coordinates":84},[85,86],9.15917,45.19205,{"lat":86,"lon":85},[89,91],{"name":10,"role":19,"phone":7,"phoneExt":7,"email":90},"luca.arcaini@unipv.it",{"name":10,"role":44,"phone":7,"phoneExt":7,"email":7},{"facility":93,"status":63,"city":94,"state":7,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Hospital Clínic de Barcelona","Barcelona","08036","Spain","ES",{"type":34,"coordinates":99},[100,101],2.15899,41.38879,{"lat":101,"lon":100},[104,106,108],{"name":105,"role":19,"phone":7,"phoneExt":7,"email":7},"ARMANDO LÓPEZ GUILLERMO, MD",{"name":7,"role":19,"phone":7,"phoneExt":7,"email":107},"alopezg@clinic.cat",{"name":109,"role":44,"phone":7,"phoneExt":7,"email":7},"Armando Hospital Clínic de Barcelona, MD",{"facility":111,"status":28,"city":112,"state":7,"zip":113,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Oncology Institute of Southern Switzerland","Bellinzona","6500","Switzerland","CH",{"type":34,"coordinates":117},[118,119],9.01703,46.19278,{"lat":119,"lon":118},[122,125],{"name":123,"role":19,"phone":7,"phoneExt":7,"email":124},"Maria Cristina Pirosa, MD","maria.pirosa@eoc.ch",{"name":123,"role":44,"phone":7,"phoneExt":7,"email":7},{"facility":127,"status":28,"city":128,"state":7,"zip":129,"country":130,"countryCode":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"University Hospitals Dorset","Bournemouth","BH7 7DW","United Kingdom","UK",{"type":34,"coordinates":133},[134,135],-1.8795,50.72048,{"lat":135,"lon":134},[138,141],{"name":139,"role":19,"phone":7,"phoneExt":7,"email":140},"Renata Walewska, MD","Renata.Walewska@uhd.nhs.uk",{"name":139,"role":44,"phone":7,"phoneExt":7,"email":7},{"type":143,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100570839","integrated-molecular-and-clinical-profiling-of-transformed-splenic-marginal-zone-lymphoma-100570839",false,"NCT06712459","Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma","Inclusion Criteria:\n\n1. Adults aged 18 years or older, regardless of the gender;\n2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease);\n3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available;\n4. Availability of the baseline and follow-up annotations.\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":153,"type":154},100,"ESTIMATED","OBSERVATIONAL","Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.",[158],"Transformed Splenic Marginal Zone Lymphoma","2026-01-15",{"date":161,"type":162},"2026-01-16","ACTUAL",{"date":164,"type":162},"2025-10-13",{"date":166,"type":154},"2029-03",{"name":5,"class":6},7]